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Abstract
Backround: Radiolabeled OTSA101, a monoclonal antibody targeting synovial
sarcoma (SS) developed by OncoTherapy Science, was used to treat relapsing SS
metastases following a theranostic procedure: in case of significant 111In-OTSA101
tumor uptake and favorable biodistribution, patient was randomly treated with
370/1110 MBq 90Y-OTSA101. Monte Carlo-based 3D dosimetry integrating time-activity
curves in VOI was performed on 111In-OTSA101 repeated SPECT/CT. Estimated
absorbed doses (AD) in normal tissues were compared to biological side effects and to
the admitted maximal tolerated absorbed dose (MTD) in normal organs. Results in the
tumors were also compared to disease evolution.
Results: Biodistribution and tracer quantification were analyzed on repeated
SPECT/CT acquisitions performed after injection of 111In-OTSA101 in 19/20 included
patients. SPECT images were warped to a common coordinates system with
deformable registration. Volumes of interest (VOI) for various lesions and normal tissues
were drawn on the first CT acquisition and reported to all the SPECT images. Tracer
quantification and residence time of 111In-OTSA101 in VOI were used to evaluate the
estimated absorbed doses per MBq of 90Y-OTSA101 by means of Monte Carlo
simulations (GATE). A visual scale analysis was applied to assess tumor uptake (grades 0
to 4) and results were compared to the automated quantification. Results were then
compared to biological side effects reported in the selected patients treated with
90Y-OTSA101 but also to disease response to treatment.
After screening, 8/20 patients were treated with 370 or 1110 MBq 90Y-OTSA101. All
demonstrated medullary toxicity, only one presented with transient grade 3 liver
toxicity due to disease progression, and two patients presented with transient grade 1
renal toxicity. Median absorbed doses were the highest in the liver (median, 0.64
cGy/MBq; [0.27−1.07]) being far lower than the 20 Gy liver MTD, and the lowest in
bone marrow (median, 0.09 cGy/MBq; [0.02−0.18]) being closer to the 2 Gy bone
marrow MTD. Most of the patients demonstrated progressive disease on RECIST criteria
during patient follow-up. 111In-OTSA101 tumors tracer uptake visually appeared highly
heterogeneous in inter- and intra-patient analyses, independently of tumor
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sizes, with variable kinetics. The majority of visual grades corresponded to the
automated computed ones. Estimated absorbed doses in the 95 supra-centimetric
selected lesions ranged from 0.01 to 0.71 cGy per injected MBq (median, 0.22
cGy/MBq). The maximal tumor AD obtained was 11.5 Gy.
Conclusions: 3D dosimetry results can explain the observed toxicity and tumors
response. Despite an intense visual 111In-OTSA101 liver uptake, liver toxicity was not
the dose limiting factor conversely to bone marrow toxicity. Even though tumors
111In-OTSA101 avidity was visually obvious for treated patients, the low estimated
tumors AD obtained by 3D dosimetry explain the lack of tumor response.
Keywords: Targeted radionuclide therapy, Absorbed dose estimation, Monoclonal
antibody, Synovial sarcoma, Monte Carlo simulation
Background
Synovial sarcomas (SS) are rare tumors accounting for 2.5 to 10% of all soft tissue sar-
comas worldwide and for 2% of all malignant neoplasms, affecting mostly teenagers and
young adults. Treatment rely on surgery and radiotherapy at initial stage, and chemother-
apy (doxorubicin and/or ifosfamide) at metastatic stage with then a median survival of
only 12 months.
Genome-wide gene expression profile analysis has revealed that the gene encoding
frizzled homolog 10 (FZD10), a 7-transmenbrane receptor and member of the Wnt sig-
naling receptor family, was overexpressed in SS, yet undetectable in normal human tissues
excepting placenta [1–4]. OncoTherapy Science Inc. has developed a chimeric human-
ized monoclonal antibody (mAb) against FZD10, named OTSA101. In mouse xenograft
model, DTPA 90Y radiolabeled OTSA101 (90Y-OTSA101) was shown to exhibit signif-
icant antitumor activity following a single intravenous injection [1] without significant
toxicities, allowing for a first-in-man phase I trial.
This trial, named Synfrizz, was conducted on a theranostic model of radionuclide ther-
apy with a two-phase approach: a screening phase followed by a therapeutic phase in
case patient fulfilled the defined criteria. The screening phase evaluated clinical and bio-
logical parameters and studied the biodistribution and tumor avidity of 111In-OTSA101
on repeated SPECT/CT acquisitions. As usually observed in radioimmunotherapy, the
liver concentrated a large amount of radioactivity and was at that time considered to
be the organ at risk. Therefore, the treatment therapeutic window was evaluated with
two parameters helping to screen the patients for therapy: tumor 111In-OTSA101 uptake
intensity visually compared to mediastinal blood pool uptake on SPECT/CT acquisitions,
and a liver estimated absorbed dose (AD) performed on repeated 2D whole body acqui-
sitions. If at least one lesion demonstrated a tracer uptake greater than mediastinum and
estimated liver AD would be less than liver MTD (20 Gy) when using the maximum activ-
ity of 90Y-OTSA101, patient was randomly treated with 370/1110 MBq 90Y-OTSA101 in
the treatment phase.
Radionuclide therapy efficacy theoretically relies on a selective high and prolonged
tumor uptake and a low normal tissue uptake with rapid wash-out of the vectorised thera-
peutic particle emitter radionuclide. This would result in high tumor AD and low normal
tissue AD, widening the therapeutic window. This can only be evaluated on repeated
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scintigraphies over a long period of time, at least close to therapeutic radionuclide phys-
ical half-life. Radioactivity quantification in regions of interest drawn on tumors and
normal tissues can be performed on planar scintigraphy (2D) but organs superposition
limits its capacity to precisely approach AD. 3D quantification performed on SPECT/CT
images has been proposedwith improved results when compared to 2D, e.g., [5, 6] (among
others), but is not yet widely available. Indeed, ADs may be estimated by means of several
methods, such as the MIRD approach using S-values for doses at organ-level [7, 8], dose
point kernel (DPK)-based convolution [9–11], or Monte Carlo (MC) for doses at pixel-
level. MC is considered the reference method, and several comparisons with the others
methods were performed and analyzed [10, 12–14].
In this paper, we present an ancillary retrospectively study focused on predicting the
AD that would have been delivered by 90Y-OTSA101 based on 3D Monte Carlo AD esti-
mation applied on diagnostic imaging performed in the screening phase of the trial, and
compared our results to observed toxicity and disease evolution in treated patients.
Methods
Patients
From 2012 to 2014, 20 metastatic SS patients that could not be treated with any other
treatment were enrolled in the phase I clinical trial, which was previously approved
by local authorities (ANSM; ClinicalTrials.gov Identifier: NCT01469975). Ten patients
fulfilled the criteria for radionuclide therapy. Two died before they could receive the treat-
ment, leading to a total of eight treated patients. SPECT/CT data were gathered from 19
patients, with one patient excluded due to incomplete data. Patients’ characteristics will
be described in a separate clinical publication reporting all the data obtained in the trial,
as well as radiopharmaceuticals.
Radiopharmaceutical
OTSA101-DTPA was labeled with 111In or 90Y according to a modified protocol [1].
Overall, 275 MBq of high purity 111In-chloride (specific activity >185 GBq/μg indium)
in diluted hydrochloric acid (Covidien, Petten, The Netherlands) or 1665 MBq of 90Y-
chloride (IBA-Cis bio, Saclay, France) were added to 2.25 mg of OTSA101-DTPA in
the presence of acetate buffer and was incubated 90 min at 37 °C. At the end of the
labeling, 0.8 mg of EDTA-2Na was added to the mixture solution. The radiochemical
purity (RCP) was assayed with a gamma isotope TLC analyzer (Raytest, Courbevoie,
France) using ITLC-SG (Biodex Tec-control black, Biodex, NY, USA) and 0.9% sodium
chloride solution as mobile phase. 111In-OTSA101 or 90Y-OTSA101 remained at the
origin, whereas unbound 111In or 90Y migrated with an Rf of 0.9–1. The radiochemi-
cal purity of radiolabeled OTSA101-DTPA was routinely over 90% before injection. In
order to verify immunogenicity of humanized monoclonal antibody against FZD10, all
patients were systematically followed up by evaluation of human anti-mouse antibodies.
No immunogenicity has been observed.
Imaging
The acquisition protocol comprised six SPECT/CT and whole body planar emission
scans, acquired at time points 1, 5, 24, 48, 72, and 144 h following intravenous injection of
approximately 185 MBq of 111In-OTSA101. The exact times of the six acquisitions were
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extracted from the image DICOM header. The first six patients’ images were acquired
with a Philips BrightView XCT device, and the remaining images using a Tandem Dis-
covery NM/CT 670 from GE Medical Systems with two heads. Indium-111 principal
gamma ray emissions are at 171 and 245 keV. A double energy window scatter subtrac-
tion method was applied. The photopeaks in keV were in the range of 153.9–188.1 and
220.5–269.5, respectively, and the scatter window was 198.6–219.6. A medium energy
general purpose/parallel (MEGP/PARA) collimator with hexagonal holes was employed.
The acquisitions were performed with two table steps for a total of 30 min. For each
step, a 180◦ step-and-shoot rotation was carried out, with 6° angle increment, provid-
ing 60 projection frames thanks to the two heads. Planar images were 1024 × 256 with
scan velocity of 10 cm min−1. The 45-s CT acquisitions were performed right after the
SPECT acquisitions, covering a large part of the body (92 cm, from patient’s neck to
below the pelvic region). They were reconstructed with 0.976562× 0.976562× 1.25 mm3
voxel size. More details regarding these devices are to be found in [15]. SPECT sampling
was 4.18 × 4.18 × 4.18 mm3. SPECT images were reconstructed with the ordered-subset
expectation maximization (OSEM) algorithm provided by the manufacturer. All images
were reconstructed with the same software version (Xeleris 3.0) and parameter sets, with
ten iterations and five subsets used. Attenuation correction was applied with attenua-
tion maps derived from the CT images. Images were corrected using the “Resolution
Recovery” package, while taking collimator-detector response functions into account.
Image registration
To compensate for patient motion between acquisitions, deformable image registration
(DIR) was performed between the time series’ first CT image, acquired at H0+1hour,
and the five others. The DIR algorithm was based on B-splines with mutual information
[16]. This method was previously reported in the literature, for example in [17, 18]. This
step’s uncertainty was estimated at less than 2 mm. The five CTs were warped using the
obtained deformation vector field (DVF). The six images were averaged in a single 3D
image, denoted avCT enabling us to reduce noise. This last step being optional but has
been found to provide superior image quality than initial CT. SPECT images were also
warped with the same resampled DVFs in order to obtain motion compensated SPECT
series [18]. Impact of breathing motion during images acquisition has not been evaluated
here but is a source of additional uncertainty.
Volumes of interest: organs and lesions
The analysis was focused on several volumes of interest (VOI): liver, spleen, heart, and
bone marrow (BM), as well as the right and left kidneys. Contours were delineated on
the first CT image. For BM, L2 − L4 lumbar vertebrae were contoured as proposed in
[19]. Among the studied patients, SS was generally associated withmetastases comprising
a large number of potentially identifiable lesions, mostly in the lungs. An expert physi-
cian (ALG) delineated a representative set of lesions (up to 25), regardless of the amount
of activities depicted on SPECT images. Some lesions were selected owing to their high
uptake values on SPECT, whereas others were chosen based only on avCT. Only lesions
with a maximum diameter >1 cm were considered. For each patient, between 1 and 25
lesions were considered, resulting in a total of 95. For each VOI, volumes and mass were
computed using the avCT images. Mass was estimated by converting Hounsfield units
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(HU) into mass, while taking into account the voxel volume of 1.19 mm3. Images are
illustrated in Fig. 1.
Analysis of the 3D activity distribution
We denote Ax(t) the activity measured in voxel x at time t. Voxels were expressed in
number of counts on the SPECT images. The conversion into activity (MBq) requires a
calibration factor estimated by imaging a known activity amount, preferably under scat-
ter and attenuation conditions close to patient imaging [8]. A patient-specific calibration
factor (cps/MBq) was estimated by taking the total number of counts on the 1h SPECT
image divided by the patient total activity weighted by the fraction of activity in the FOV
(FAF). The FAF, which corresponds to the percentage of activity within the limited SPECT
FOV, was estimated on the 1h whole body planar images. The SPECT FOV dimensions
and localization were projected onto the planar images. Using the whole body images, the
FAF was then calculated as the number of counts in this FOV divided by the total num-
ber of counts. The patient total activity at 1H was estimated by the injected activity, decay
corrected, as the 1h images were acquired before urination. Activity was subsequently
expressed in percentage of injected activity per kilogram of tissue (%IA/kg). For a VOI h,
the total activity in the volume at instant t was obtained by summing up activities for all
Fig. 1 Illustration of initial data (CT and SPECT images), time-integrated activity distribution, and absorbed
dose distribution
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voxels belonging to h: Ah(t) =
∑
x Ax(t) ∀x ∈ h. These mean activities were associated
with their standard deviation (SD) computed as SDh(t) =
√∑
x Ax(t)2 − Ah(t)2 ∀x ∈ h.
The SD corresponds to the activity heterogeneity within the VOI.
For the lesions, peak values were considered, because lesions were usually small (a few
centimeters in diameter) and depicted partial volume effect tending to artificially reduce
the activity near lesion boundaries. In analogy to the SUV-peak value for PET images [20],
we defined Apeakh (t), the peak activity in VOI h at time t, as the mean activity measured
in the spherical subregion contained in h exhibiting the maximum activity. The volume
of this spherical region was set at 1 cc. In order to identify this peak subregion, SPECT
images were convolved by a spherical mean filter kernel with a radius corresponding to
the desired volume (in this case, about 6.2 mm to obtained a sphere of 1cc). The positions
of the maximum voxel values in the time sequence of filtered images were averaged and
the average position was used as the center of the peak sub-region. The value Apeakh (t)
was defined as the mean activity in that subregion and expressed in %IA/kg. This method
implicitly assumes that peak uptake locations in region are stable as a function of time.
It was mostly verified for the data presented here, the standard deviation of the peak
locations being low, around 5 mm. Taking into account the SPECT image resolution, the
peak value is considered as stable.
Time-integrated cumulated activities in voxels x [7, 8, 21] were computed as follows:
A˜(x) = ∫ ∞0 Ax(t)dt. Like in [12], the integrals were approximated using with a two-step
method. First, the trapezoid method was used on the first part of the curve, with the
activity at injection time extrapolated with a linear fit towards 0 (uptake part). Second, the
integration’s final part, from the last time point (H0+144 h) to infinity, was modeled using
a fit of amono-exponential functionAx(t) = A0e−λt of the curve’s last two or three points.
Three points were generally used, except if the maximum uptake value was reached after
the last three points. If activity increases in the last time point, an artificial time point is
added to force the activity to decrease (at 60 h, with half of the maximum activity). Time-
integrated activity A˜h for a VOI h was obtained with the same method applied to the
mean Ah(t) or peak activity Apeakh (t) and expressed in MBq h per mass and per MBq of
injected activity: MBq h/kg/IA. The fitting procedure was performed with the weighted
Levenberg-Marquardt optimization method and 100 iterations, with the weights being
the standard deviation of the activities inside the VOI. Ceres-Solver [22] was used.
3D absorbed dose estimation
Absorbed dose distributions with 90Y were computed by Monte Carlo simulation using
GATE [23, 24]. Time-integrated activity (TIA), i.e., the estimated total number of dis-
integrations, were estimated for all voxels and used as a 3D source map. 111In TIA,
distribution was substituted with 90Y half-life, assuming that the biological half-life is
the same between the two radionuclides. As 90Y undergoes β− decay (to stable 90Zr),
the source was simulated as an electron source with isotropic emission and a continu-
ous energy spectra obtained from the 90Y decay (mean of 933.7 keV, maximum of 2280.1
keV) simulated with Geant4, using the ENSDF database (Evaluated Nuclear Data Cen-
ter, Brookhaven National Laboratory). While 90Y is known to also produce some gamma
radiation (511 keV, 2.186 MeV), this was passed over because this amounted to less than
<0.01% of yield. All electromagnetic processes were taken into account (Photoelectric,
Compton, and Rayleigh scattering, pair production, ionization, bremsstrahlung, positron
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annihilation, multiple scattering) owing to the emstandard_opt1 physic list of Geant4.
Production cuts were set at 5 mm as differences with AD distribution obtained with lower
values were negligible. Hounsfield units of the CT images were converted into patient
material properties using Schneider’s method [25]. CT images were resampled like the
SPECT images to 4.183 mm3 voxel size in order to reduce computation time. AD distribu-
tion was recorded with a DoseActor [24] of the same voxel size. The simulations involved
approximately 5× 108 emitted electrons. Statistical uncertainties were <1.5% for all vox-
els having >25% of the maximum AD by the patient. One simulation took about 20 h of
computation time on single core of a conventional computer (PC, Linux, Intel Xeon CPU
E5-1660, 3.3 GHz). The total 19 simulations were performed under 2h30 with a cluster of
200 CPUs. At the end of the simulation, the obtained AD distributions were scaled to cor-
respond to the total number of disintegrations computed from the time-integrated image.
The AD was expressed in cGy per administered activity (cGy/MBq). Mean AD in a VOI
was computed by averaging the deposited energy in all voxels belonging to the VOI, and
dividing by the total mass of the VOI.
Visual grading
In analogy with the investigation of endocrine tumors [26, 27], a visual scale analysis
was proposed. This procedure applied an uptake scoring scale comparing tumor uptake
intensity to mediastinal blood pool background on SPECT-CT. Grade 0: no tracer uptake
by tumor; grade 1: tumor tracer uptake lower than the mediastinum; grade 2: equal to
the mediastinum; grade 3: greater than the mediastinum; and grade 4: equal to the most
intense normal tissue uptake. In the phase I trial, patients were scheduled to be referred
for 90Y-OTSA101 treatment if at least one lesion demonstrated a tracer uptake higher
than mediastinum at any time of SPECT acquisition. Visual analysis was then compared
to automated quantification based on the same set of rules, though computed as based on
the AD estimation in the liver and the mediastinum. The scale is presented in Table 1.
Results
Toxicity. The whole list of toxicities will be detailed in a separate clinical article. We focus
here on the biological toxicity concerning the liver, kidney, and bone marrow functions
using OMS grades of toxicity, evaluated on blood tests at D7, D14, and D28. Bone mar-
row toxicity as presented in Table 2 is separated in grades L (leucopenia, lymphopenia), T
(thrombocytopenia), and A (anemia).Whole patients demonstrated significantmedullary
toxicity unresolved for 4/8 patients during follow-up. Only one patient had a grade 3
alteration of liver enzymes not related to treatment but to disease progression unre-
solved before patient death, and two patients presented with a transient grade 1 increased
creatinine.
Table 1 Grading scale for lesions, with uptake compared to mediastinum and liver uptake
Grade Lesion uptake ratio
Grade 0 Lesion uptake < 20% mediast. uptake
Grade I Lesion uptake < 80% mediast. uptake
Grade II Lesion uptake > 80% and < 120% mediast. uptake
Grade III Lesion uptake > 120% mediast. and < 80% liver uptakes
Grade IV Lesion uptake > 120% liver uptake






















2 370 1.49 0 0.17 2 0 1 0.25 0
3 1110 3.39 0 0.27 3 1 1 0.76 1
3 bis 1110 3.39 0 0.27 3 1 1 0.76 0
8 1110 8.78 0 1.47 3 1 3 2.27 1
10 370 2.51 0 0.33 1 0 1 0.76 0
11 1110 4.79 0 1.38 3 0 0 2.12 0
14 370 2.97 3 0.54 2 3 3 0.98 0
15 1110 11.22 0 1.33 4 3 2 2.48 0
20 1110 8.52 0 1.81 2 3 1 2.62 0
Absorbed dose (AD) are indicated in Gy for the liver, bone marrow, and kidneys. Toxicity grades are indicated for the liver,
leucopenia/lymphopenia (L), thrombocytopenia (T), anemia (A), and kidneys. Patient 3 has been treated with two injections
Grading. In Table 3, the grades of all lesions exceeding grade 0 have been listed. The
majority of visual grades corresponded to computed grades, excepted for five lesions. For
one lesion (P11), a large difference between visual grading (IV) and computed grading (II)
was observed.
Biodistribution and kinetics. 111In-OTSA101 biodistribution was similar to that usu-
ally observed in radioimmunotherapy with a predominant radiotracer uptake in the liver.
Figure 2 shows the time activity curves of 111In-OTSA101 for different organs. Values
are expressed in %IA/kg. Based on this figure, a similar behavior was observed with all
VOI showing a monotonous decrease since the first time point, excepting the liver, which
depicted a characteristic accumulation phase between 1 and 24 h after injection, followed
by a clearance phase. Only three patients (P1, P3, P13) did not exhibit this accumulation
phase, maybe situated between 5 and 24h. No particular uptakes by other organs than the
Table 3 Visual (column 3) and computed (column 4) grading for lesions with grade higher than 0
P. L. V grade C grade Com.
5 1 I I
2 III III
8a 1 III III
2 III III
3 IV IV
4 IV III Lower grade




11a 1 IV II Lower grade
2 I I
3 II I Lower grade
4 I I
5 I I
15a 1 II I
17 1 II II
20a 1 III III
2 III II Lower grade
aPatients that have been indeed treated
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Fig. 2 Variation of %IA/kg with time for several organs (liver, heart, kidneys, bone marrow, and spleen). The
patient weight in kilograms is also displayed
liver were observed. Relative activities differed from patient to patient. Maximum values
for liver uptake ranged from approximately 8% IA/kg (P3) up to>18% (P17). No clear cor-
relation was found between the patient weights and accumulated activities (r = −0.75),
yet there was a tendency towards smaller activities for higher patient weights. We also
noticed the very fast clearance phase from the heart as commonly observed. Of note, the
standard deviations of all activity points have not been displayed in this report, but ranged
between 0.2 and 3.8%/kg, with the highest values observed for the heart.
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Figure 3 displays the tracer kinetics as the % peak-activity/kg in relation with time for
several lesions compared to the activity observed in the liver. Heterogeneous results were
observed. Several lesions (P3, P5, P8, P12) exhibited typical two-phase curves with an
initial accumulation phase reaching a maximum at around 24–48 h, thus at a later time
point than the liver peak. By contrast, other lesions did not display an accumulation
phase. Except for a few specific lesions, the activity concentrations in the lesions were
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Fig. 3 Variation of %peak-activity/kg with time for several lesions compared to the liver. Patients with a “T”
indicated that they had been treated
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high uptake, suggesting an antibody accumulation in the tumor. Lesions smaller than 1
cm in diameter were not studied due to the limited resolution capacity of SPECT: their
segmentation was found to be very difficult and unreliable.
Absorbed dose. MedianADswere the highest in the liver (median, 0.64 cGy/MBq; [0.27–
1.07]), followed by the mediastinal blood pool (median, 0.27 cGy/MBq, [0.13–0.41]),
kidneys (median, 0.17 cGy/MBq, [0.05–0.27]), and bonemarrow (median, 0.09 cGy/MBq,
[0.02–0.18]). ADs to VOI are displayed in Fig. 4, and the ratios between lesions and liver in
Fig. 5. The liver not only showed the highest values but also the largest standard deviation
for all patients.
Lesions exhibits very heterogeneous values independently of the tumor size. The lesion
uptakes in P3 and P8 were clearly visible. Figure 5 shows that no lesions, excepting one,
displayed a higher AD than the liver. Large heterogeneity was observed, even within the
lesions of the same patient. While several lesions demonstrated no radiotracer uptake
and seemed not to capture the mAb, others showed good uptake (P8, P3). Estimated ADs
in the 95 selected lesions ranged from 0.01 to 0.82 cGy per injected MBq (median, 0.25
cGy/MBq).
Half-lives. Figure 6 illustrates box plots of the effective half-lives for all organs and
patients. The box depicts first and third quartiles, with the band inside the box represent-
ing the median, and the whiskers’ ends the minimum and maximum values. Outliers that
were not included between the whiskers have been plotted as dots.
Discussion
The main observation is that heterogeneous uptakes were observed among patients, with
the liver presenting the most significant activity. In the following, we consider the 90Y-





















Fig. 4 Estimated absorbed dose in cGy by injected activity (MBq) in several VOI and lesions for all patients.
Patient number is indicated close to the few lesions with the largest absorbed doses



























Fig. 5 Ratio between absorbed doses by lesions and the liver for all patients
the patient was treated or not. Liver doses would range from 4.3 to 13 Gy. This intense
radiophamaceutical uptake by the liver was expected as commonly observed in mAb
radioimmunotherapy studies, e.g., [28]. However, those values are below the maximum
tolerated dose (MTD), estimated around 20 Gy [29]. AD was generally low in other















Indium 111 half-life (67.3 h)
Fig. 6 Effective half-lives of several organs (liver, heart, kidneys, bone marrow, spleen, and whole patient) for
all patients. Physical half-life of 111Indium is indicated by the horizontal line
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kidneys), and below their respective MTD. The same threshold is usually applied to the
kidneys and other tissues else than bone marrow and was never reached by the estimated
doses. This correlates with the absence of significant liver or renal toxicity observed in
the treated patients. However, for bone marrow, five patients would have received more
than 1.8 Gy, which is close to the MTD, estimated around 2 Gy [30]. This threshold was
obtained by Benua in 1962 who observed no unacceptable hematological complication
in case of BMAD less than 2 Gy in 131I treated patients [31]. Patient to patient variation
was large.We considered the inter-patient coefficient of variation (CV, standard deviation
over mean): ADs for organs depicted CV between 33 and 42%, except for bone marrow
where it was 50%. Considering that partial volume effect [32] was only partly corrected
here (thanks to the resolution recovery option of the reconstruction software), caution
should be taken about the AD to bone marrow that may be larger than the one computed
here.
We performed PET and scintigraphic acquisitions using bremsstrahlung from 90Y to
match true dose rate images in two patients. However, the too low activity in whole
body and tumors stopped us to proceed to further acquisitions for the remaining treated
patients. Any quantification would have been impossible as normal organs other than the
liver as well as the lesions were not visible.
Considering only the eight patients that actually received 90Y-OTSA101 injection, large
medullary toxicity were observed. However, unlike [33] who found that 3D BM dosimetry
on SPECT incorporating radiobiological modeling data and applying Monte Carlo calcu-
lation tended to correlate with haematotoxicity, no correlation was clearly found between
the AD and observed toxicities. There is suspicion of unchelated 90Y that could not be
predicted by the 111In images, but it cannot be proven. Moreover, patients had a medical
history of multiple pre-treatments that may affect myelotoxicity.
The observed 111In-OTSA101 uptakes were visually obvious for only few patients.
Hence, we cannot confirm high FZD10 antigen expression for the majority of patients SS
metastases. This is different to genes screening in SS lesions as FZD10 was found to be
highly expressed in 8/13 SS tumors, expressed in 4/13 and absent in one [34]. For exam-
ple, for patients demonstrating intense lesion uptake (P3, P8), AD was estimated to be
approximately 8.5 and 11.5 Gy, respectively, when their livers would receive 3.8 and 11.1
Gy. Patient 3 disease was stabilized after the first injection allowing for a second injection
6 months later. Unfortunately, lesions had a 28% RECIST progression 2 months later and
the patient died of profuse hemoptysis 3 months after the second injection. Except for
these two patients, lesions of the remaining six treated patients received far less than 10
Gy which was expected to be insufficient especially in some patients with bulky tumors.
By comparison, high tumors ADs has been recently evaluated as up to 468 Gy with
radionuclide therapy using 177Lu-PSMA to treat prostate adenocarcinoma metastases,
with great impact on disease-free survival [35]. Dosimetry results explain the poor clinical
benefice observed. This would be related to a low FZD10 expression in SS metastases.
We observed a tendency towards a delayed 111In-OTSA101 uptake in the lesions, at a
maximum of 24–48h. Only one lesion of the 19 patients showed a lesion-to-liver AD ratio
>1 (P3). We observed in Fig. 6 that all organs excepting the liver showed effective half-
life lower than the 111In physical half-life of 67.3 h, meaning that the mAb tended to be
eliminated from these organs, as expected. For the liver, we observed an estimated effec-
tive half-life slightly exceeding the physical half-life for some patients. One assumption to
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explain this fact is an accumulation in that region due to the circulating mAb. Another
assumption could be the degradation of the radiopharmaceutical. As expected, for the
VOI “WholeBody” (when merging all the image voxels), the effective half-life was slightly
lower than 111In half-life, most likely due to the natural physiological clearance. Con-
sidering lesions >0.5 cGy/MBq, there was one for P3 and seven for P8. Their effective
half-lives was between 69 and 102 h, thus larger than the 111In half-life (data not shown).
This observation may indicate a late mAb uptake and accumulation by these lesions.
Regarding the proposed tumor uptake grading, the majority of visual grades corre-
sponded to the automated computed ones. However, two patients (P10, P11) that were
treated, would not have been treated if the automated grading have been used. Indeed,
the visual grade corresponded to the maximal tracer uptake observed at any time in the
most 111In-OTSA101 avid lesion giving a sort of “SUVmax” when computed grades and
therefore tumors AD result from the integrated time activity curve and reflect more the
total tumor radioactivity exposition.
Conclusions
In this study, the quantitative 3D analysis of the biodistribution and dosimetry of a radi-
olabeled monoclonal antibody against FZD10 was performed for the first time in SS
metastic patients. A complete workflow including images calibration, deformable regis-
tration, time activity curves integration, and Monte Carlo simulation has been proposed
and applied on 19 patients repeated SPECT/CT. The proposed method indirectly con-
firm FZD-10 antigen expression in some patients with SSmetastases, but 111In-OTSA101
lesions uptake appeared too low in half of the patients on the basis of visual grad-
ing. On the basis of automated tumor uptake grading method two other patients would
not have been treated as tumor/mediastinum ratio was finally too low. Estimated ADs
in the liver and bone marrow explain biological toxicity, and the too low AD in the
tumors explain the lack of tumor response. Patient-specific quantitative 3D biodistribu-
tion and dosimetry appears feasible and seems to be essential in the theranostic approach
for predicting toxicity, defining activity prescription, and studying absorbed dose-effect
relationships.
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